Caris Life Sciences (CAI) Cash from Financing Activities (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Cash from Financing Activities of $824000.0 for Q1 2026, down 35.88% year-over-year from $1.3 million in Q1 2025, and down 75.76% quarter-over-quarter from $3.4 million in Q4 2025.
Caris Life Sciences (CAI) Cash from Financing Activities (2024 - 2026) Analysis & Trends
Caris Life Sciences' Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $824000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 35.88% year-over-year to $824000.0; the TTM figure through Mar 2026 stood at $664.5 million (changed N/A YoY), while the FY2025 annual figure was $665.0 million, up 232.01% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $824000.0, down from $3.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $681.4 million in Q2 2025, with the low at -$21.1 million in Q3 2025.
- The 3-year median for Cash from Financing Activities is $824000.0 (2026), against an average of $95.2 million.
- Peak annual rise in Cash from Financing Activities reached 1403.98% in 2025, while the deepest fall reached 24349.43% in 2025.
- Caris Life Sciences' Cash from Financing Activities stood at $226000.0 in 2024, then jumped by 1403.98% to $3.4 million in 2025, then tumbled by 75.76% to $824000.0 in 2026.
- Business Quant data shows CAI's Cash from Financing Activities at $824000.0 in Q1 2026, $3.4 million in Q4 2025, and -$21.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | -36.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.90 Mn |
| Jun 30, 2026 | -36.90 Mn |
| Mar 31, 2026 | 824,000.00 |
| Mar 31, 2026 | 824,000.00 |
| Dec 31, 2025 | 3.40 Mn |
| Dec 31, 2025 | 3.40 Mn |
| Sep 30, 2025 | -21.10 Mn |
| Sep 30, 2025 | -21.10 Mn |
| Jun 30, 2025 | 681.40 Mn |
| Jun 30, 2025 | 681.40 Mn |
| Mar 31, 2025 | 1.29 Mn |
| Mar 31, 2025 | 1.29 Mn |
| Dec 31, 2024 | 226,000.00 |
| Dec 31, 2024 | 226,000.00 |
| Sep 30, 2024 | 87,000.00 |
| Sep 30, 2024 | 87,000.00 |